# Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema

> **NCT01343823** · PHASE2 · TERMINATED · sponsor: **Shire** · enrollment: 79 (actual)

## Conditions studied

- ACE Inhibitor Induced Angioedema

## Interventions

- **DRUG:** ecallantide 60 mg
- **DRUG:** ecallantide 30 mg
- **DRUG:** ecallantide 10 mg
- **DRUG:** placebo
- **DRUG:** placebo match for 30 mg ecallantide arm
- **DRUG:** placebo match for 10 mg ecallantide arm

## Key facts

- **NCT ID:** NCT01343823
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06-01
- **Primary completion:** 2012-06-01
- **Final completion:** 2012-06-01
- **Target enrollment:** 79 (ACTUAL)
- **Why stopped:** Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was substantially higher than described in medical literature.
- **Last updated:** 2021-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01343823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01343823, "Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01343823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*